Travere Therapeutics Inc (TVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.86B
Last updated: Nov 17, 2026 at 11:06 AM ET
Travere Therapeutics Inc (TVTX) Stock Forecast
Analysts expect Travere Therapeutics (TVTX) to earn $0.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $765.32M. Of 15 analysts, 14 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.93, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 13.3% |
| Buy | 12 | 80.0% |
| Hold | 1 | 6.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 922.6% and revenue estimates rise 49.0%.
- Fiscal year ending Dec 31, 2026
- $0.53
- EPS consensus, revenue $765.32M
- Fiscal year ending Dec 31, 2027
- $5.42
- EPS consensus, revenue $1.14B
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.53 | $0.33 to $0.81 | 7 | $765.32M | $739.68M to $782.20M | 14 |
| Dec 31, 2027 | $5.42 | $4.16 to $6.63 | 8 | $1.14B | $882.67M to $1.38B | 14 |
Quarterly Estimates
The EPS consensus rises from $0.48 for the quarter ending Dec 31, 2026 to $1.05 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.48 | $0.09 to $0.99 | 16 | $243.08M | $206.78M to $279.30M | 16 |
| Mar 31, 2027 | $1.05 | $0.80 to $1.27 | 5 | $254.72M | $231.81M to $282.20M | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 3 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 69.9% from $1.76.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.53 | $1.67 | $1.74 | $1.74 | $1.76 | -69.7% |
| Fiscal year ending Dec 31, 2027 | $5.42 | $5.70 | $5.67 | $5.67 | $5.49 | -1.3% |
| Quarter ending Mar 31, 2027 | $1.05 | $1.05 | $1.01 | $1.01 | $0.96 | +9.6% |
Frequently Asked Questions About TVTX
What is the TVTX stock forecast?
Consensus analyst estimates put Travere Therapeutics's EPS at $0.53 for the fiscal year ending Dec 31, 2026, on revenue of $765.32M. The consensus rating from 15 analysts is Buy.
How do analysts rate TVTX stock?
Of 15 analysts covering Travere Therapeutics, 2 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TVTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.53, with estimates from $0.33 to $0.81 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $5.42, with estimates from $4.16 to $6.63 from 8 analysts.
What revenue do analysts expect from Travere Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $765.32M, with estimates from $739.68M to $782.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.14B, with estimates from $882.67M to $1.38B.
How many analysts cover TVTX?
15 analysts rate Travere Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TVTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts